Effect of Extra Virgin Olive Oil on Anthropometric Indices, Inflammatory and Cardiometabolic Markers: a Systematic Review and Meta-Analysis of Randomized Clinical Trials
Morvaridzadeh M, Cohen AA, Heshmati J, Alami M, Berrougui H, Zoubdane N, Pizarro AB, Khalil A
The Journal of nutrition · 24 citas
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
- Consumo medido con
- No se indica
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- Canadian Institutes of Health Research
- Gobierno
- CIHR
- Subvenciones
- Canadian Institutes of Health Research (PJT-162366))
Según 2 financiadores declarados.
Publicación
- Publicado
- 2023-11-15 · J Nutr · vol. 154 · número 1 · págs. 95–120
- Editorial
- Elsevier BV
- Citado
- 33 citas · más que el 52% de estudios similares · 0.5× el promedio de su campo
- Referencias
- 75 trabajos
- Acceso
- Lectura gratuita
- Áreas de investigación
- Edible Oils Quality and Analysis · Nutritional Studies and Diet · Fatty Acid Research and Health
- Palabras clave
- extra virgin olive oil, cardiometabolic risk factors, insulin resistance, HOMA-IR, inflammatory markers, lipid profile, blood pressure, anthropometric indices, cardiovascular disease prevention, dietary intervention, C-reactive protein, interleukin-6, TNF-α, apolipoprotein A-I, apolipoprotein B, lipoprotein(a), body mass index
- MeSH
- humans, cardiovascular diseases, inflammation mediators, randomized controlled trials as topic, insulins, olive oil
8 autores
- Mojgan Morvaridzadeh🇨🇦Université de Sherbrooke
- Alan Arthur Cohen🇺🇸Columbia University
- Javad Heshmati🇨🇦Université de Sherbrooke
- Mehdi Alami🇨🇦🇲🇦Université de Sherbrooke; Université Sultan Moulay Slimane
- Hicham Berrougui🇨🇦🇲🇦Université de Sherbrooke; Université Sultan Moulay Slimane
- Nada Zoubdane🇨🇦Université de Sherbrooke
- Ana Beatriz Pizarro🇨🇴Fundación Valle del Lili
- Abdelouahed Khalil🇨🇦 · autor de correspondenciaUniversité de Sherbrooke
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
A large body of literature associated extra virgin olive oil (EVOO) consumption with low risk of cardiovascular disease and mortality. However, findings from clinical trials related to EVOO consumption on blood pressure, lipid profile, and anthropometric and inflammation parameters are not univocal.
Objectives
The aim of this systematic review and meta-analysis was to evaluate the effect of EVOO consumption on cardiometabolic risk factors and inflammatory mediators.
Methods
We searched PubMed/MEDLINE, Scopus, and Cochrane up through 31 March, 2023, without any particular language limitations, in order to identify randomized controlled trials (RCTs) that examined the effects of EVOO consumption on cardiometabolic risk factors, inflammatory mediators, and anthropometric indices. Outcomes were summarized as standardized mean difference (SMD) with 95% confidence intervals (CIs) estimated from Hedge's g and random-effects modeling. Heterogeneity was assessed by Cochran Q-statistic and quantified (I2).
Results
Thirty-three trials involving 2020 participants were included. EVOO consumption was associated with a significant decrease in insulin (n = 10; SMD: -0.28; 95% CI: -0.51, -0.05; I2 = 48.57%) and homeostasis model assessment of insulin resistance levels (HOMA-IR) (n = 9; SMD: -0.19; 95% CI: -0.35, -0.03; I2 = 00.00%). This meta-analysis indicated no significant effect of consuming EVOO on fasting blood glucose, triglycerides, total cholesterol, low density lipoproteins, very low density lipoproteins, high density lipoproteins, Apolipoprotein (Apo) A-I and B, lipoprotein a, blood pressure, body mass index, waist circumference, waist to hip ratio, C-reactive protein, interleukin-6, interleukin-10, and tumor necrosis factor α levels (P > 0.05).
Conclusions
The present evidence supports a beneficial effect of EVOO consumption on serum insulin levels and HOMA-IR. However, larger well-designed RCTs are still required to evaluate the effect of EVOO on cardiometabolic risk biomarkers. This study was registered in PROSPERO as CRD42023409125.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.